Ultra Market Research | United States EGFR and HER2 Targeted NSCLC Market
United States EGFR and HER2 Targeted NSCLC Market
Report ID : 862
Category : United-States(US),Healthcare-Companies
No Of Pages : 148
Published on: November 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Introduction
The United States EGFR & HER2 targeted NSCLC (non-small cell lung cancer) market has emerged as a focal point in oncology, driven by advancements in precision medicine. EGFR (Epidermal Growth Factor Receptor) and HER2 (Human Epidermal Growth Factor Receptor 2) are critical biomarkers that have paved the way for targeted therapies, significantly improving patient outcomes. Applications of these targeted therapies include first-line treatment, adjuvant settings, and combating resistance in advanced NSCLC stages. Recent trends highlight the growing adoption of next-generation sequencing (NGS) for biomarker detection and the integration of novel therapies like antibody-drug conjugates (ADCs). The market is also witnessing robust collaborations between biotechnology firms and academic institutions to develop next-gen therapeutics.
Segmentation
Molecular Diagnostics Biomarker Testing
EGFR Mutation Detection
HER2 Amplification Testing
Others Companion Diagnostics Liquid Biopsy
Circulating Tumor DNA (ctDNA)
Circulating Tumor Cells (CTCs)
Others
Therapeutics Targeted Therapies
Tyrosine Kinase Inhibitors (TKIs)
HER2-Specific Monoclonal Antibodies
Others Immunotherapies Combination Therapies
EGFR-TKI + Anti-HER2 Therapy
EGFR-TKI + Immunotherapy
Others
End-User Applications Hospitals Specialized Cancer Centers Research Institutes Homecare Settings
List of Market Players
AstraZeneca (UK)
Genentech (USA)
Novartis (Switzerland)
Pfizer Inc. (USA)
Amgen Inc. (USA)
Eli Lilly and Company (USA)
Bristol-Myers Squibb (USA)
Boehringer Ingelheim (Germany)
Merck & Co. (USA)
Takeda Pharmaceutical (Japan)
Sanofi (France)
Seagen Inc. (USA)
Daiichi Sankyo (Japan)
Johnson & Johnson (USA)
Blueprint Medicines (USA)
Drivers
The United States EGFR & HER2 targeted NSCLC market is driven by advancements in personalized medicine, where therapies are tailored based on genetic profiles. Rising prevalence of NSCLC, accounting for over 80% of lung cancer cases, has created a pressing demand for effective therapies. Breakthroughs in EGFR and HER2-targeted therapies, such as osimertinib and trastuzumab deruxtecan, have revolutionized treatment paradigms. Favorable FDA approvals and increasing adoption of NGS technology have streamlined biomarker testing. Additionally, strong investment in R&D by pharmaceutical giants supports ongoing innovation.
Restraints
Despite its potential, the market faces challenges such as the high cost of targeted therapies, limiting accessibility for many patients. Resistance to EGFR-TKIs and HER2 therapies over time poses a significant hurdle, necessitating alternative approaches. Regulatory complexities and lengthy clinical trial processes can delay drug commercialization. Limited awareness among certain healthcare providers regarding emerging HER2-targeted options further hampers adoption. Moreover, disparities in access to cutting-edge diagnostic technologies create an unequal healthcare landscape.
Opportunities
The growing focus on early-stage NSCLC treatments offers immense opportunities for the market. Development of combination therapies, integrating EGFR and HER2 inhibitors with immune checkpoint inhibitors, presents a promising treatment avenue. Expansion of liquid biopsy technology ensures minimally invasive biomarker detection, broadening diagnostic reach. Collaborations between biopharma companies and AI-driven platforms are facilitating drug discovery and enhancing clinical trial efficiencies. Additionally, the introduction of biosimilars is expected to make these advanced treatments more affordable, expanding market penetration.
Trend
The latest trend in the United States EGFR & HER2 targeted NSCLC market revolves around next-generation EGFR inhibitors that address resistance mutations like T790M and C797S. HER2-directed ADCs are gaining traction for their precision in targeting cancer cells while sparing healthy tissue. Real-world evidence (RWE) studies are increasingly shaping regulatory decisions, ensuring therapies are both effective and practical in diverse settings. Patient-centric care models, integrating telehealth and genomic counseling, are on the rise. Emerging partnerships between diagnostics and therapeutic companies aim to deliver holistic solutions.
Table 1: Key Biomarkers for EGFR & HER2 Testing in NSCLC
Table 2: Molecular Diagnostics Segmentation by Technology
Table 3: List of Approved EGFR & HER2 Targeted Therapies in the United States
Table 4: Pipeline Drugs for EGFR & HER2 NSCLC Treatments with Clinical Trial Phases
Table 5: Market Drivers for EGFR & HER2 Targeted NSCLC in the United States
Table 6: Challenges Impacting Market Growth
Table 7: Opportunities in the United States EGFR & HER2 Targeted NSCLC Market
Table 8: Key Trends Shaping the Market Landscape
Table 9: Leading Market Players and Headquarters
Table 10: Key Target Audience for Market Research Reports
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings Internal and external proprietary databases, relevant patent and regulatory databases National government documents, statistical databases and market reports News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process Middle Circle Represents – Source of Information Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc. Helps in validating and strengthening the secondary research findings Further develops the analysis team’s expertise and market understanding Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers Purchasing managers, technical personnel, distributors and resellers Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment Macro-economic indicators: GDP, etc. Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities. Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps:
2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach. 2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United States EGFR and HER2 Targeted NSCLC Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region.
This report provides market size of United States EGFR and HER2 Targeted NSCLC Market for the past year and forecasts for the next six years. United States EGFR and HER2 Targeted NSCLC Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United States EGFR and HER2 Targeted NSCLC Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Global Skincare Treatment from different application industries in different regions.
Segmentation
Molecular Diagnostics Biomarker Testing
EGFR Mutation Detection
HER2 Amplification Testing
Others Companion Diagnostics Liquid Biopsy
Circulating Tumor DNA (ctDNA)
Circulating Tumor Cells (CTCs)
Others
Therapeutics Targeted Therapies
Tyrosine Kinase Inhibitors (TKIs)
HER2-Specific Monoclonal Antibodies
Others Immunotherapies Combination Therapies
EGFR-TKI + Anti-HER2 Therapy
EGFR-TKI + Immunotherapy
Others
End-User Applications Hospitals Specialized Cancer Centers Research Institutes Homecare Settings
